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Background: Acute pulmonary edema (APE) has a poor prognosis in the general population. Mortality associated
with APE in patients with end-stage renal disease (ESRD) is especially high, although specific predictors are not well
understood. This study aimed to determine the potential predictive factors of outcome in patients with ESRD
presenting with APE.
Methods: Sixty-eight patients with ESRD (mean age, 68.9 ± 9.9 years; males, 66.2%; median duration of
maintenance hemodialysis, 55.5 months) presenting with APE to a single tertiary medical center were
retrospectively evaluated. The effects of patients’ characteristics, cardiovascular risk factors, variables at hospital
presentation, and clinical presentation patterns on all-cause mortality were evaluated.
Results: Throughout the observational period (median follow-up period, 575 days; range, 10–2546 days), 32 (47%)
patients died. In univariate analysis, older age, diabetes mellitus, peripheral artery or aortic disease, hypotension,
atrial fibrillation rhythm, anemia, and hypoalbuminemia were associated with higher mortality, whereas hospital
presentation from midnight to 8 am was associated with lower mortality. In multivariate analysis, age (hazard ratio
(HR) = 1.05, 95% confidential interval (CI) 1.01–1.09, p = 0.018), presence of peripheral artery or aortic disease (HR =
3.36, 95% CI 1.52–7.42, p = 0.003), time of presentation from midnight to 8 am (HR = 0.40, 95% CI 0.15–0.99, p = 0.
047), and atrial fibrillation rhythm at presentation (HR = 3.12, 95% CI 1.04–9.13, p = 0.044) were significantly
independently associated with mortality.
Conclusions: Our findings indicate important predictive roles of the clinical presentation pattern specific to ESRD
patients, as well as their characteristics, including cardiovascular risk factors.
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The number of patients on maintenance hemodialysis suf-
fering from end-stage renal disease (ESRD) is approxi-
mately 400,000 in the USA [1] and approximately 300,000
in Japan [2]. Cardiovascular disease accounts for 50% of
death among these patients [3], with congestive heart fail-
ure comprising approximately 25% of death in Japan [2].* Correspondence: snakano@saitama-med.ac.jp
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symptom of acute heart failure requiring hospital admis-
sion, is associated with considerable mortality [4, 5]. This
condition is accompanied by severe respiratory distress,
audible crackles, and orthopnea and is verified by chest X-
ray [6]. In addition to respiratory support, initial treatment
of APE aims to ameliorate preload and afterload [7]. In the
general population, factors such as older age, hypotension,
hyponatremia, and anemia at presentation are predictors of
poor outcome in patients presenting with acute heartle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
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hypotension predict mortality [5].
Despite high mortality (approximately 80% mortality at
5 years) and morbidity of APE [12, 13], evidence regarding
APE in patients undergoing maintenance hemodialysis is
lacking. Patients with ESRD on maintenance hemodialysis
should be considered as different from the general popula-
tion because they have different cardiovascular disease
characteristics and responses to therapy [1, 3]. Moreover,
periodic hemodialysis therapy jeopardizes their preload to
fluctuate non-physiologically. Therefore, risk stratification
and therapeutic guidelines according to clinical presenta-
tion described in acute heart failure in the general popula-
tion, such as the clinical scenario [9, 14], may not be
applicable to this cohort.
Considering the distinct patho-physiology and high
mortality, specific predictors in patients with ESRD on
maintenance hemodialysis presenting with APE need to
be investigated. This study aimed to determine the ef-
fects of demographics, non-cardiovascular and cardio-
vascular factors, and clinical presentation on all-cause
mortality in patients on maintenance hemodialysis pre-
senting with APE.
Methods
Study design and population
The medical records of 132 patients with ESRD on main-
tenance hemodialysis presenting with APE who required
emergent admission were retrospectively reviewed. Pa-
tients were admitted to the Intensive Care Unit or Cardiac
Care Unit in Saitama Medical University International
Medical Center because of APE between April 2007 and
October 2015. Maintenance hemodialysis was defined asa b
Fig. 1 Chest X-rays of included and excluded patients. a Included patient:
b Excluded patient: A 58-year-old woman with marginal X-ray findings sho
admission, this patient had hypotension (systolic blood pressure 70 mmHg
(white blood cell count 23,140/μl, serum C-reactive protein 20.0 mg/dl). A s
these abnormal parameters and X-ray findings were subsequently resolved
marginal X-ray findings showing abnormal pleural and pulmonary shadow
pulmonary metastases secondary to renal cancerperformance of maintenance hemodialysis for 3 months
or longer before admission. Patients were included if they
showed pulmonary edema on an initial chest X-ray as de-
termined by two observers (S.N. and S.H.). Patients who
showed marginal X-ray findings with their clinical course
that were inconsistent with APE were excluded after dis-
cussion with a third observer using clinical information.
Figure 1 shows representative X-rays of the included and
excluded patients. Other exclusion criteria are shown in
Fig. 2. Patients who required immediate invasive therapy
for acute cardiovascular collapse (such as acute coronary
syndrome) were excluded because the impact of sudden
cardiac dysfunction and procedure-related outcomes may
cancel the effects of the factors specifically related to
maintenance hemodialysis or ESRD.
Data collection
Baseline demographics of patients, maintenance hemodialysis
data, and coexisting or previous conditions were recorded.
Hypertension was defined as current or previous treatment
with anti-hypertensive medication. Diabetes mellitus was
defined as treatment with anti-diabetic medication or
hemoglobin A1c concentration of ≥6.5% [15]. Dyslipidemia
was defined as treatment with anti-dyslipidemic medication
or fasting serum concentration of low-density lipoprotein
cholesterol ≥160 mg/dl, high-density lipoprotein cholesterol
≤40 mg/dl, or total cholesterol ≥240 mg/dl [16].
Malignancy, peripheral artery and aortic disease (e.g.,
aortic dissection and aortic aneurysm, either treated or
untreated), previous myocardial infarction, and previous
cerebral infarction and hemorrhage were recorded. Pre-
vious cardiovascular interventions, such as percutaneous
coronary intervention, coronary artery bypass grafting,c
A 58-year-old woman with X-ray findings typical of pulmonary edema.
wing right-side-dominant infiltration and modest cardiomegaly. Upon
), fever (>38°), and elevated levels of acute inflammatory biomarkers
ystemic inflammatory response due to infection was suspected, and
with antibiotic therapy. c (excluded patient) An 81-year-old man with
s (arrows) and pneumothorax (arrowhead). The patient had pleural and
Fig. 2 Flow diagram of eligibility of patients
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surgery for peripheral artery disease, valvular surgery,
and pacemaker/cardio-defibrillator implantation, were
recorded. Coronary artery anatomy collected from cor-
onary angiography during the index or previous
hospitalization was recorded. Medications that were ad-
ministered prior to presentation were recorded.
For the prehospital course, the time elapsed from
symptom (defined as dyspnea on exertion, paroxysmal
nocturnal dyspnea, or orthopnea) onset to arrival was
recorded, and the patients were divided into two groups
(>72 and ≤72 h); in the >72-h group, their symptoms
started before the last dialysis session. Hospital presenta-
tion time was recorded and divided into the following
three groups: 8 am to 4 pm, 4 pm to midnight, and mid-
night to 8 am [17]. The 2-day interdialytic gap, body
weight gain, and body weight gain rate were recorded.
Vital signs, arterial blood gases (before initiating spe-
cific respiratory support other than oxygen supplement
alone), and laboratory findings at presentation were re-
corded. Echocardiographic and electrocardiographic var-
iables were recorded.
Initial therapy within 48 h was recorded, and changes
in subjective dyspnea and vital signs after the initial sin-
gle hemodialysis session were evaluated.
Outcome measures
The associations between independent factors at presen-
tation and all-cause death throughout the observation
period were evaluated.
Statistical analysis
Continuous variables are expressed as the mean ± stand-
ard deviation or median (first to third quartile) and cat-
egorical variables as number (%). The Shapiro–Wilk testwas performed for testing normal distribution. Univari-
ate Cox proportional regression analyses were performed
to identify the association between independent variables
and all-cause death. Subsequently, multivariate Cox pro-
portional regression analyses were performed to identify
potential predictors of all-cause death. Because there are
no established predictors of mortality in patients on
maintenance hemodialysis presenting with APE, a multi-
variate model was constructed with independent vari-
ables using p < 0.05 in univariate analysis. Kaplan–Meier
analyses were performed to test the predictive value of
independent variables for mortality with the log-rank
test. All statistical analyses were performed using JMP
Pro.11.2.0 (SAS Institute, Inc., Cary, USA).
Results
Baseline characteristics, variables of the prehospital
course and at presentation, and initial therapy and
response of patients
A flow diagram of the patients’ eligibility is shown in
Fig. 2. Sixty-eight patients were included in the final
analysis. Baseline characteristics, data on maintenance
hemodialysis, and coexisting or previous medical condi-
tions are shown in Table 1. Peripheral artery disease was
observed in 20 patients, including one with previous
lower limb amputation. Aortic disease was observed in
seven patients, including five with previous aortic sur-
gery for their aortic dissection or aneurysm.
Coronary artery anatomy was only evaluated in 50
(73.5%) patients. Medications and previous cardiovascu-
lar interventions are shown in Additional file 1: Tables
S1 and S2.
Variables of the prehospital course and at presentation
are shown in Table 2. Most patients were hypertensive
at presentation. Their initial therapy within 48 h after
Table 1 Baseline characteristics of patients and univariate Cox proportional analysis for all-cause death
Total (n = 68) Hazard ratio p
Demographics
Age (years) 68.9 ± 9.9 1.06 0.003*
Male, n (%) 45 (66.2) 2.03 0.08
Body mass index (kg/m2) 21.1 (19.1–24.3) 0.95 0.30
Maintenance hemodialysis data
Etiology of kidney disease
Diabetic nephropathy, n (%) 44 (64.7) 1.16 0.70
Nephrosclerosis, n (%) 6 (8.8) 1.74 0.33
Others, n (%) 18 (26.5) 0.65 0.30
Duration of maintenance hemodialysis (months) 55.5 (27.3–85.5) 1.00 0.95
Frequency (times/week) 3 (3–3) NA NA
Each hemodialysis time (hours/day) 4.0 (4.0–4.0) 1.05 0.88
Coexisting/previous conditions, n (%)
Previous acute pulmonary edema 24 (35.3) 1.09 0.82
Hypertension 60 (88.2) 0.64 0.44
Diabetes mellitus 52 (76.5) 2.47 0.04*
Dyslipidemia 34 (50.0) 0.97 0.94
Current smoking 10 (14.7) 0.98 0.97
Malignancy 11 (16.2) 1.12 0.82
Peripheral artery or aortic disease 21 (30.9) 2.98 0.005*
Previous myocardial infarction 21 (30.9) 1.00 0.99
Previous cerebral infarction 9 (13.2) 2.17 0.12
Previous cerebral hemorrhage 4 (5.9) 1.08 0.91
Coronary anatomy (n = 50)
Normal coronary artery, n (%) 10 (20.0) 0.87 0.80
Left main trunk disease, n (%) 3 (6.0) 0.95 0.96
Triple vessel disease, n (%) 10 (20.0) 1.54 0.38
Continuous variables are shown as the mean ± SD or median (first to third quartile) and categorical variables as number (%)
NA not analyzed
*p<0.05
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file 1: Table S3; 56 (82.4%) patients required emergent
hemodialysis, including continuous hemodialysis for
expected hemodynamic instability. Most patients (86.4%)
demonstrated relief of subjective dyspnea and hypertension
after initial renal replacement therapy.
Univariate Cox proportional analyses for all-cause
mortality
The median follow-up period was 575 days (174–966:
range 10–2546 days), and the total follow-up time was
135.4 years. Throughout the observational period, 32 (47%)
patients died from the following causes: myocardial infarc-
tion (n = 7), low-output circulatory failure (n = 6), acute
pulmonary edema (n = 6), sudden death (n = 3), and other
non-cardiovascular causes, such as malignancy (n = 3), liver
failure (n = 3), pneumonia (n = 2), sepsis (n = 1), and anunknown cause (n = 1). Index in-hospital death was
observed in six (8.8%) patients. The potential cause of
in-hospital death was cardiovascular events in all six
patients, including low-output circulatory failure (n = 5)
and acute myocardial infarction with shock (n = 1).
However, most of these patients were complicated by
sepsis or lower airway infection.
In univariate analysis, older age, the presence of
diabetes mellitus, and peripheral artery disease or aor-
tic disease were associated with higher all-cause mor-
tality in the whole observational period. Lower
systolic blood pressure, hematocrit, serum albumin
levels, and AF rhythm at presentation were also sig-
nificantly associated with higher mortality. The time
of hospital presentation from midnight to 8 am was
significantly associated with lower mortality (Tables 1
and 2).
Table 2 Variables of the prehospital course and at hospital
presentation, and univariate Cox proportional analysis for all-
cause death




>72 h from onset to
arrival, n (%)
13 (19.1) 0.90 0.83
Time of hospital
presentation, n (%)
- 8 am to 4 pm 10 (14.7) 1.88 0.17
- 4 pm to midnight 22 (32.4) 1.96 0.07
- Midnight to 8 am 36 (52.9) 0.38 0.007†
2-day interdialytic gap, n (%) 37 (54.4) 1.09 0.81
Body weight gain (kg) 2.0 (1.0–4.0) 1.00 0.95




182 (159–205) 0.99 0.04†
Diastolic blood pressure
(mmHg)
94 (72–115) 0.99 0.13
Heart rate (bpm) 102 (90–116) 0.98 0.15
Respiratory rate (/minute) 26 (21–30) 0.97 0.35
Saturation of peripheral
oxygen (%)
97 (92–99) 0.98 0.42
Arterial blood gases
pH 7.37 (7.26–7.44) 6.98 0.19
pCO2 (mmHg) 38.8 (34.5–50.6) 0.99 0.26
pO2 (mmHg) 83.4 (61.4–97.5) 1.00 0.72
HCO3− (mmol/l) 22.1 (19.6–24.6) 1.03 0.60
Echocardiographic variables
(Teichholz method)
LVEDVI (ml/m2) 77.6 (62.8–97.8) 1.00 0.53
LVESVI (ml/m2) 36.9 (25.9–50.1) 1.00 0.73
Left ventricular ejection
fraction (%)
53 (41.3–61) 0.99 0.61
Left ventricular mass index
(g/m2)




10 (14.7) 3.34 0.01*
Artificially paced, n (%) 0 (0) NA NA
Left ventricular
hypertrophy, n (%)
12 (17.6) 1.22 0.65
QRS duration (ms) 112 (101.5–120) 1.01 0.41
Laboratory findings
White blood cell count
(×103/μl)
10.2 (7.7–12.4) 0.97 0.56
Hematocrit (%) 34.4 ± 5.3 0.92 0.03†
Platelet count (×103/μl) 213.2 ± 69.2 0.99 0.07
Blood urea nitrogen (mg/dl) 47.0 ± 16.1 1.00 0.66
Table 2 Variables of the prehospital course and at hospital
presentation, and univariate Cox proportional analysis for all-
cause death (Continued)
Creatinine (mg/dl) 8.1 ± 2.3 0.88 0.08
Aspartate aminotransferase
(U/l)
20 (15–30) 1.01 0.16
Alanine aminotransferase
(U/l)
14 (8–17) 1.01 0.10
Albumin (g/dl) 3.7 ± 0.4 0.28 0.007†
Blood glucose (mg/dl) 161 (120.3–217.3) 1.00 0.31
Sodium (mmol/l) 139.1 ± 3.1 0.93 0.17
Potassium (mmol/l) 4.8 (4.3–5.4) 1.04 0.84
Chloride (mmol/l) 102.0 ± 3.2 0.95 0.31
Calcium (mg/dl), n = 61 8.9 ± 0.7 0.98 0.96
Phosphate (mg/dl), n = 56 5.0 (3.6–5.8) 1.06 0.61
C-reactive protein (mg/dl) 0.53 (0.15–1.85) 1.01 0.89
Continuous variables are shown as the mean ± SD or median (first to third
quartile) and categorical variables as number (%)
LVEDVI left ventricular end-diastolic volume index, LVESVI left ventricular end-
systolic volume index, NA not analyzed
*p<0.05 with a positive association, †p<0.05 with a negative association
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ate Cox regression analysis
Variables that were significantly associated with all-
cause mortality were included in the multivariate
regression model. Age (p = 0.018), presence of per-
ipheral artery or aortic disease (p = 0.003), time of
presentation from midnight to 8 am (p = 0.047),
and AF rhythm at presentation (p = 0.044) were
significantly independently associated with mortality
(Table 3).
Kaplan–Meier analyses using potential predictors
(Fig. 3) showed significantly higher all-cause mortal-
ity in patients with peripheral artery or aortic disease
(p = 0.002) and with AF (p = 0.003). Lower mortality
was found in patients presenting from midnight to 8
am than in those presenting during the rest of the
day (p = 0.007).Discussion
The current study aimed to determine the potential
predictors of mortality in patients with ESRD present-
ing with APE. We found that older age, the presence
of peripheral or aortic disease, and AF rhythm at hos-
pital presentation were independently associated with
higher mortality, whereas the time of hospital presen-
tation from midnight to 8 am was associated with
lower mortality. These findings suggest an important
role of the specific clinical presentation pattern in
predicting mortality, as well as the importance of
readily accessible acute data, including cardiovascular
parameters.
Table 3 Factors associated with all-cause death
HR 95% CI p
Age 1.05 1.01–1.09 0.018*
Diabetes mellitus 1.70 0.65–5.45 0.298
Peripheral artery or aortic disease 3.36 1.52–7.42 0.003*
Presentation from midnight to 8 am 0.40 0.15–0.99 0.047†
Systolic blood pressure 1.00 0.99–1.01 0.956
Atrial fibrillation rhythm 3.12 1.04–9.13 0.044*
Hematocrit 0.96 0.88–1.05 0.414
Albumin 0.30 0.08–1.02 0.053
Cox proportional regression analyses were performed
HR hazard ratio, CI confidence interval
*p < 0.05 with a positive association, †p < 0.05 with a negative association
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hemodialysis
Acute pulmonary edema may be caused by cardiac or
non-cardiac etiology. Distinguishing cardiac from non-
cardiac APE using a single parameter, such as left ven-
tricular contractility, is often difficult [18–20], especially
in patients with ESRD whose fluid status is susceptible
to excessive sodium and water intake. In these patients,
underlying abnormal cardiac function is common be-
cause of volume overload (e.g., anemia, arteriovenous
fistulas, and dialysis therapy per se), leading to left ven-
tricular dilatation, or pressure overload (e.g., hyperten-
sion and atherosclerosis), leading to left ventricular
hypertrophy and potential relative myocardial ischemia
[3]. We speculate that their potential cardiovascular
pathology may directly or indirectly lead to the develop-
ment of APE. Therefore, comprehensive assessment of
cardiovascular information, including previous or coex-
isting cardiovascular disease, and echocardiographic and
electrocardiographic findings as candidate contributorsFig. 3 Kaplan–Meier analyses. Kaplan–Meier analyses using the potential pr
peripheral artery disease (PAD) or aortic disease (a) and in those with atrial
from midnight to 8 am (c)of APE may be reasonable, rather than distinguishing
cardiac from non-cardiac etiology.Effect of comorbidities and cardiac function
Some studies focused on acute heart failure or pulmon-
ary edema in patients with ESRD. We found that older
age was significantly associated with mortality, which is
consistent with previous studies [12, 21].
In our study, some conventional cardiovascular risk
factors in the general population, such as coexisting dys-
lipidemia, hypertension, or obesity, were not associated
with mortality. This finding may be partly explained by the
reverse epidemiology in which these factors may play pro-
tective roles in under-nutrition [22]. In contrast, in our
study, diabetes mellitus was associated with mortality in
univariate analysis. Diabetes mellitus and coexisting macro-
and microvascular diseases are associated with a poor prog-
nosis in patients on maintenance hemodialysis [12, 23–25].
We also found that the presence of peripheral artery or aor-
tic disease was a strong predictor of mortality.
We found that AF rhythm at presentation was associ-
ated with mortality. Previous studies have reported an as-
sociation between AF and all-cause mortality in patients
with ESRD [21, 26]. Interestingly, as demonstrated in our
study, the association of AF with poor outcome was re-
ported to be superior to that of left ventricular ejection
fraction in patients with ESRD [21]. In our study, the me-
dian heart rate and duration of maintenance hemodialysis
were comparable between patients with and without AF.
Although the exact mechanism of a worse outcome asso-
ciated with AF is unclear, potential acceleration of atrial
remodeling caused by hemodialytic therapy and a high
prevalence of embolic or bleeding events [21, 27] have
been reported to be involved in high mortality.edictors showed significantly higher all-cause mortality in patients with
fibrillation (AF, b). Lower mortality was found in patients presenting
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was associated with mortality. The acid–base imbalance
observed in our cohort was mild (median pH, 7.37) and
had little effect on outcome in patients with ESRD who
are commonly exposed to mild acidosis [28].
Effect of the clinical presentation pattern
In patients undergoing maintenance hemodialysis, a sub-
stantial amount of fluid is retained in interdialytic period
and quickly removed at hemodialysis treatment. This
leads to non-physiological fluctuation of preload. Fluid
retention is the main cause of emergent hospitalization
in patients undergoing maintenance hemodialysis and is
associated with mortality [13, 18]. However, greater
weight gain or a 2-day gap after the last hemodialysis
session was not associated with mortality in our study.
We found that hospital presentation from midnight to
8 am was significantly associated with lower mortality.
The association between nighttime presentation and
outcomes in general populations of patients with acute
heart failure has not been determined [29, 30]. The def-
inition of nighttime presentation varies among studies;
in the current study, we recognized nighttime as the
time from midnight to 8 am to eliminate the evening
time when many patients were still awake. The concept
of circadian fluid shift may partly explain this finding.
Upon lying down at night, fluid that is accumulated dur-
ing the daytime redistributes rostrally by gravity, result-
ing in fluid shift to the lungs, as well as the upper airway
[31]. We speculate that APE developing at night may
simply result from a fluid shift due to volume overload,
whereas APE developing during the daytime might be
attributable to underlying factors other than simple vol-
ume overload, such as an altered cardiovascular condi-
tion. Additionally, the potential presence of obstructive
sleep apnea, which is a prevalent condition in patients
with ESRD (50–70%) [32], should be considered as a
contributing factor to the better prognosis in patients
who presented at night, although our study lacks poly-
somnographic data. In patients with concurrent ESRD
and obstructive sleep apnea, rostral overnight fluid shift
is associated with the severity of obstructive sleep apnea
[33], possibly via an increase in the jugular vein volume
and pharyngeal water content [34]. Hence, nighttime
rostral fluid shift, which may lead to acute pulmonary
edema, may be enhanced by obstructive sleep apnea.
From a therapeutic viewpoint, rostral fluid shift resulting
from fluid overload can be corrected by a single emer-
gent hemodialysis session. Moreover, positive airway
pressure, which was performed as initial respiratory
management in some of our patients (Additional file 1:
Table S3), might have helped to alleviate symptoms in
patients with obstructive sleep apnea by unloading the
inspiratory muscles and left ventricular afterload [35].Interestingly, patients presenting at night had a higher
median systolic blood pressure than did those presenting
during the rest of the day. Elevated systolic blood pres-
sure at presentation, possibly related to increased filling
pressure and sympathetic hyperactivity, may favorably
respond to pharmacological therapy, such as vasodila-
tors, and is associated with lower mortality [9, 11]. In
the majority of our patients who presented at night, re-
lief of dyspnea and hypertension was observed after a
single emergent hemodialysis session. We speculate that
these characteristic initial therapeutic strategies and
their responses may be a reflection of the hemodynamics
and neurohormonal responses that are specific to pa-
tients with ESRD.
The effect of delay from symptom onset to presenta-
tion has been discussed for general heart failure [36–40].
In our study, a delay in presenting to the hospital (>72 h
after initial symptoms) was not associated with mortal-
ity. We consider that because of the meticulous titration
of the fluid balance at regular clinic visits, prolonged
symptoms may be less common in patients with ESRD
than in the general population. This situation indicates
that the role of a delay in presentation is less meaningful
in patients with ESRD than in the general population.Limitations
This study has some limitations. First, it was an observa-
tional study conducted at a single tertiary center and in-
cluded relatively small number of patients. A center-specific
bias involving medical transfer systems should be considered
as a potential social and infrastructural factor that contrib-
uted to the better prognosis of patients who presented at
night. However, we included objective variables accessible at
presentation and the clinical presentation pattern and found
potential predictors of mortality from our longitudinal ob-
servation. Second, coronary artery anatomy, which may be
an important predictor of mortality, was evaluated in only
73.5% of patients; therefore, we might have underestimated
the implication of coronary artery anatomy. Clinically ac-
cessible parameters, such as echocardiographic or electro-
cardiographic variables, might have partially compensated
for the insufficient coronary information.Conclusions
In patients on maintenance hemodialysis presenting with
APE, older age, the presence of peripheral artery or aortic
disease, and AF rhythm at presentation were significantly
associated with higher mortality, whereas the time of hos-
pital presentation from midnight to 8 am was significantly
associated with lower mortality. Our findings indicate im-
portant predictive roles of the clinical presentation pattern
specific to patients with ESRD, as well as their characteris-
tics, including cardiovascular risk factors.
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